Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 451K | 0 | 0 | 0 | 0 |
| Gross Profit | 3K | 0 | -1K | -1K | -1K |
| Operating Income | -2M | -765K | -880K | -1M | -948K |
| EBITDA | -930K | -764K | -879K | -1M | -947K |
| Net Income | -1M | -2K | -1M | 435K | -782K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.54
+4.96% today
1Y Change
-33.16%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
XTL Biopharmaceuticals Ltd. (XTLB) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $2.54 and down 33.2% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow -136.5% with operating margin -481.6% and ROIC -29.7%. Valuation already assumes a fairly strong business story at price/sales 19.2. Stock Foundry combines XTLB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XTLB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XTLB Max Drawdown
-74.88%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XTLB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$782.0K
-279.8% YoY
Free Cash Flow
-$851.0K
+18.9% YoY
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
0.7%
Net Margin
-227.7%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 451K | 0 | 0 | 0 | 0 |
| Gross Profit | 3K | 0 | -1K | -1K | -1K |
| Operating Income | -2M | -765K | -880K | -1M | -948K |
| EBITDA | -930K | -764K | -879K | -1M | -947K |
| Net Income | -1M | -2K | -1M | 435K | -782K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 371K | 1M | 2M | 3M | 4M |
| Total Assets | 9M | 2M | 4M | 7M | 7M |
| Total Liabilities | 3M | 206K | 187K | 1M | 254K |
| Shareholder Equity | 5M | 2M | 4M | 5M | 4M |
| Total Debt | 138K | 0 | 0 | 0 | 0 |
| Net Debt | -233K | -1M | -2M | -3M | -4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
850K
+19.0% YoY
Capital Expenditures
1K
Free Cash Flow
851K
+18.9% YoY
Key ratios
Gross Margin
0.7%
Operating Margin
-481.6%
Net Margin
-227.7%
ROE
-26.8%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.